Date Log
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
A review on role of oncogene (KRAS) & tumor suppressor gene (TP53) in colorectal cancer
Corresponding Author(s) : Nori Kodanda Ram
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 12 No. 4 (2024): 2024 Volume -12 - Issue 4
Abstract
Multiple oncogenic mutations and the cross stalk between normal pathways are the sources of the complexity involved in Colorectal Cancer (CRC) therapy. Mutated from of a type of gene called protooncogenes, which is involved in normal cell growth and disunion. A tumor suppressor gene, also known as an antioncogene, controls a cell's division and replication. Activation of different protooncogenes can lead to the carcinogenesis of colorectal cancer. Despite important progress attained in the symptomatic and therapeutic management of patients with colorectal cancer, there has been newly a significant growth in the prevalence of large intestine cancer in individuals below the age of 50 years. Primal inception of colorectal cancer has a complex incidence of mucinous histology, a more remote site, a different deoxyribonucleic acid (DNA) methylation profile, and a reduced survival rate. Understanding the pathophysiological mechanisms underlying this oncogenesis process may also make it easier to identify new targets for treatment.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- Vundavilli, H., Datta, A., Sima, C., Hua, J., Lopes, R., & Bittner, M. (2021). Targeting oncogenic mutations in colorectal cancer using cryptotanshinone. PLoS One, 16(2), e0247190.
- The etiology and pathogenesis.oncol.2024;9;2046 of colorectal cancer; Weledji EP,clin
- Centelles, J. J. (2012). General aspects of colorectal cancer. International Scholarly Research Notices, 2012(1), 139268.
- Rebecca L. colorectal cancer statistics,etl.2023,march,01
- Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021). Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular cancer, 20(1), 143.
- Nori Kodanda Ram et al / Int. J. of Pharmacology and Clin. Research, 8(3) 2024 [350-355]
- Qi L, Ding Y. Screening ofC Tumor Suppressor Genes in Metastatic Colorectal Cancer. Biomed Res Int. 2017;2017:2769140. doi: 10.1155/2017/2769140. Epub 2017 Apr 4. PMID: 28473981; PMCID: PMC5394352.
- The etiology and pathogenesis.oncol.2024;9;2046 of colorectal cancer; Weledji EP,clin
- [Gongmin Zhu, Lijiao Pei, Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer et al. mol cancer ,2021,20:143
- Rahman S, Garrel S, Gerber M, Maitra R, Goel S. Therapeutic Targets of KRAS in Colorectal Cancer. Cancers (Basel). 2021 Dec 11;13(24):6233. doi: 10.3390/cancers13246233. PMID: 34944853; PMCID: PMC8699097.
- Rahman S, Garrel S, Gerber M, Maitra R, Goel S. Therapeutic Targets of KRAS in Colorectal Cancer. Cancers] (Basel). 2021 Dec 11;13(24):6233. doi: 10.3390/cancers13246233. PMID: 34944853; PMCID: PMC8699097.
- Zhu, G., Pei, L., Xia, H. et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 20, 143 (2021).
- KRAS (kirsten rat sarcoma viral oncogene) is a memberMingjing Meng, Keying Zhong, Ting Jiang, Zhongqiu Liu, Hiu Yee Kwan, Tao Su,The current understanding on the impact of KRAS on colorectal cancer,Biomedicine & Pharmacotherapy, Volume140, 2021,111717,ISSN07533322.
- Nori Kodanda Ram et al / Int. J. of Pharmacology and Clin. Research, 8(3) 2024 [350-355]
- Zhu, G., Pei, L., Xia, H. et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 20, 143 (2021).
- Oncogenes and tumor suppressor genes /American cancer society w.w.w cancer organization archieved from the original on 2021/03/18.
- September 2020Innovative Journal of Medical and Health Science 10(9):1256-126110(9):1256-1261.
- The_tumor_suppressor_gene_TP53_and_colorectal_cancer_A_review
- Liz J. Hernández Borrero, Wafik S. El-Deiry,Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting,Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,Volume 1876, Issue 1,2021.
- Geny supresorowe jako molekularne markery raka jelita grubego – przegląd najnowszych doniesień Agnieszka M. Piechowska1, Monika Wawszczak1, Anna Cedro2, Stanisław Głuszek1.
- Genes chromosome cancer 2017 Nov;56(11):769-789.doi:10.1002gcc
- Nahal eshghifar, Naser farrokhi, j aherehnaji,Gastroenterology and hepatology from bed to bench 10(1),3,2017.
- Annals of new York academy of sciences /volume 910,issues /P121.139 25 january 2006.
- Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, Pani A, Scaglione F, Siena S, Sartore-Bianchi A. Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open. 2021 Jun;6(3):100156. doi: 10.1016/j.esmoop.2021.100156. Epub 2021 May 25. PMID: 34044286; PMCID: PMC8167159.
- Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun. 2019 Aug 19;10(1):3722.
References
Vundavilli, H., Datta, A., Sima, C., Hua, J., Lopes, R., & Bittner, M. (2021). Targeting oncogenic mutations in colorectal cancer using cryptotanshinone. PLoS One, 16(2), e0247190.
The etiology and pathogenesis.oncol.2024;9;2046 of colorectal cancer; Weledji EP,clin
Centelles, J. J. (2012). General aspects of colorectal cancer. International Scholarly Research Notices, 2012(1), 139268.
Rebecca L. colorectal cancer statistics,etl.2023,march,01
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021). Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Molecular cancer, 20(1), 143.
Nori Kodanda Ram et al / Int. J. of Pharmacology and Clin. Research, 8(3) 2024 [350-355]
Qi L, Ding Y. Screening ofC Tumor Suppressor Genes in Metastatic Colorectal Cancer. Biomed Res Int. 2017;2017:2769140. doi: 10.1155/2017/2769140. Epub 2017 Apr 4. PMID: 28473981; PMCID: PMC5394352.
The etiology and pathogenesis.oncol.2024;9;2046 of colorectal cancer; Weledji EP,clin
[Gongmin Zhu, Lijiao Pei, Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer et al. mol cancer ,2021,20:143
Rahman S, Garrel S, Gerber M, Maitra R, Goel S. Therapeutic Targets of KRAS in Colorectal Cancer. Cancers (Basel). 2021 Dec 11;13(24):6233. doi: 10.3390/cancers13246233. PMID: 34944853; PMCID: PMC8699097.
Rahman S, Garrel S, Gerber M, Maitra R, Goel S. Therapeutic Targets of KRAS in Colorectal Cancer. Cancers] (Basel). 2021 Dec 11;13(24):6233. doi: 10.3390/cancers13246233. PMID: 34944853; PMCID: PMC8699097.
Zhu, G., Pei, L., Xia, H. et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 20, 143 (2021).
KRAS (kirsten rat sarcoma viral oncogene) is a memberMingjing Meng, Keying Zhong, Ting Jiang, Zhongqiu Liu, Hiu Yee Kwan, Tao Su,The current understanding on the impact of KRAS on colorectal cancer,Biomedicine & Pharmacotherapy, Volume140, 2021,111717,ISSN07533322.
Nori Kodanda Ram et al / Int. J. of Pharmacology and Clin. Research, 8(3) 2024 [350-355]
Zhu, G., Pei, L., Xia, H. et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer 20, 143 (2021).
Oncogenes and tumor suppressor genes /American cancer society w.w.w cancer organization archieved from the original on 2021/03/18.
September 2020Innovative Journal of Medical and Health Science 10(9):1256-126110(9):1256-1261.
The_tumor_suppressor_gene_TP53_and_colorectal_cancer_A_review
Liz J. Hernández Borrero, Wafik S. El-Deiry,Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting,Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,Volume 1876, Issue 1,2021.
Geny supresorowe jako molekularne markery raka jelita grubego – przegląd najnowszych doniesień Agnieszka M. Piechowska1, Monika Wawszczak1, Anna Cedro2, Stanisław Głuszek1.
Genes chromosome cancer 2017 Nov;56(11):769-789.doi:10.1002gcc
Nahal eshghifar, Naser farrokhi, j aherehnaji,Gastroenterology and hepatology from bed to bench 10(1),3,2017.
Annals of new York academy of sciences /volume 910,issues /P121.139 25 january 2006.
Patelli G, Tosi F, Amatu A, Mauri G, Curaba A, Patanè DA, Pani A, Scaglione F, Siena S, Sartore-Bianchi A. Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open. 2021 Jun;6(3):100156. doi: 10.1016/j.esmoop.2021.100156. Epub 2021 May 25. PMID: 34044286; PMCID: PMC8167159.
Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. Nat Commun. 2019 Aug 19;10(1):3722.